CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, 2020

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) will announce its third quarter 2020 financial results on November 10, 2020, after the markets close. A conference call and webcast will follow at 4:30 p.m. ET to discuss results and provide a corporate update. The call can be accessed by phone at (877) 735-2860 (domestic) or (602) 563-8791 (international) with conference ID 5504037. A replay will be available for 30 days. CTI focuses on developing therapies for blood-related cancers, particularly myelofibrosis and COVID-19 treatment.

Positive

• Focus on developing novel targeted therapies for blood-related cancers.
• Active development of pacritinib, targeting unmet medical needs.

Negative

• None.

SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 5504037. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

About CTI BioPharma Corp.

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-third-quarter-2020-financial-results-on-november-10-2020-301165190.html

SOURCE CTI BioPharma Corp.

FAQ

When will CTI BioPharma report its third quarter 2020 financial results?

CTI BioPharma will report its third quarter 2020 financial results on November 10, 2020.

What time is the conference call for CTI BioPharma's financial results?

The conference call will take place at 4:30 p.m. ET on November 10, 2020.

How can I access the conference call for CTI BioPharma?

You can access the call by dialing (877) 735-2860 domestically or (602) 563-8791 internationally, using conference ID 5504037.

What is the focus of CTI BioPharma's development efforts?

CTI BioPharma focuses on novel targeted therapies for blood-related cancers and has recently started developing pacritinib for hospitalized patients with severe COVID-19.